OncoDefender-CRC, which measures the expression of colorectal cancer-specific genes, is a prognostic test capable of predicting the risk of recurrence in patients previously treated with surgical resection of a stage I/II colon cancer tumor or stage I rectal cancer tumor. The company will officially launch the test later this month, according to the news release.
Read the news release about OncoDefender-CRC.
Read other coverage about colorectal cancer prevention:
– ACG, ASGE React to NYTimes ‘Letter’ About Colonoscopy
– ACOG Urges OB/GYNs to Encourage CRC Screening in Female Patients
– University of Cincinnati Tests Cholesterol Drug to Prevent Recurrence of Colorectal Cancer
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
